araag2/HINT huggingface dataset:
Clinical trial NCT00515632 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: balaglitazone
SMILES: CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC2=CC=CC=C2C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Type 2 diabetes mellitus, being diagnosed according to the 1999 WHO criteria for at
             least 3 months

          2. Age ≥ 18 years

          3. BMI ≥ 25.0 kg/m2

          4. HbA1c ≥ 7.0 %

          5. Treatment with insulin with stable dose of at least 30 U/day (± 4 U/day), for at least
             75 days

        Exclusion Criteria:

          1. Prior or current use of any PPAR-γ agonist

          2. Recent use (< 3 months) of an investigational drug

          3. Pre-existing medical condition judged to preclude safe participation in the study

          4. Contraindication/intolerance to study medication

          5. Use of any drug which in the Investigator's opinion could interfere with the glucose
             level (e.g. systemic corticosteroids)

          6. Diagnosed or receiving medication for heart failure, NYHA I to IV

          7. Hospitalisation for a major CV event in the last 3 months, scheduled major CV
             intervention

          8. Uncontrolled treated/untreated systolic blood pressure >180 mmHg and/or diastolic
             blood pressure > 95 mmHg

          9. Known diabetic macular oedema

         10. Hematuria

         11. Serum creatinine >130 μmol/l

         12. ALT, AST, total bilirubin or alkaline phosphatase ≥ 2.5 times the upper limit of
             normal

         13. Haemoglobin significantly (in the Investigators opinion, but not more than 1 mmol/L)
             below the lower limit of normal or haemoglobinopathy interfering with valid HbA1c
             assay

         14. Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive
             methods (adequate contraceptive measures are an intrauterine device or oral
             contraceptives)

         15. Mental incapacity, unwillingness, or language barrier precluding adequate
             understanding or cooperation

         16. Abuse of alcohol or drugs, or presence of any condition that in the Investigators
             opinion may lead to poor adherence to study protocols

         17. Cancer or any clinically significant disease or disorder, except for conditions
             associated to the type 2 diabetes, which in the Investigator's opinion could interfere
             with the results of the trial
Clinical trial NCT00316719 (phase 3, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: lam group, adv group
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion criteria:

          -  Have compensated chronic hepatitis B.

          -  Have not been treated with anti HBV agents with antiproliferative activity against.
             However, previous Interferon (IFN) therapy is permitted.

          -  Ability to read, understand, and sign the informed consent.

          -  Have a positive serum HBV-DNA >= 1,000,000 copies/mL and ALT level 50-500 U/L

        Exclusion criteria:

          -  Having or suspected of having liver cancer.

          -  Co-infected with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV).

          -  Autoimmune hepatitis.

          -  Received any previous transplantation or having a plan for any transplantation.

          -  Existence of any serious complication, except hepatitis B.
Clinical trial NCT00424190 (phase 3, status: completed)
Conditions: bacterial infections
ICD codes: A49.9, A04.9, A04.8, A49.8
Drugs: iv vancomycin plus iv aztreonam, ceftaroline
SMILES: CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2, [H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires
             significant surgical intervention, or cellulitis or abscess on lower extremity which
             occurs in subjects with diabetes mellitus or well-documented peripheral vascular
             disease.

        Exclusion Criteria:

          -  Prior treatment of current cSSSI with an antimicrobial.

          -  Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior
             isolation of an organism with in vitro resistance to vancomycin or aztreonam.
Clinical trial NCT00219544 (phase 3, status: completed)
Conditions: neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: pregabalin (lyrica), pregabalin (lyrica), pregabalin (lyrica), placebo
SMILES: CC(C)C[C@H](CN)CC(O)=O, CC(C)C[C@H](CN)CC(O)=O, CC(C)C[C@H](CN)CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused
             by a lesion of the peripheral nervous system manifesting with sensory symptoms and
             signs, for at least 6 months at screening.

          -  At baseline, subjects must have completed at least 4 daily pain diaries and must have
             a mean weekly pain score equal or greater than 4.

        Exclusion Criteria:

          -  Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy;
             Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other
             entrapment-related neuropathic pain (defined as pain associated with focal nerve
             lesion produced by constriction or mechanical distortion of the nerve, within a
             fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain
             syndrome (type 1 and 2); Fibromyalgia.
Clinical trial NCT00146523 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: mifepristone, placebo
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Are 18 to 75 years of age

          -  Have a diagnosis of major depressive disorder with psychotic features (Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition [DSM IV] 296.24 or 296.34)

          -  Are able to provide written informed consent.

        Exclusion Criteria:

          -  Have a major medical problem

          -  Have previously participated in a Corlux (C-1073, mifepristone) clinical trial

          -  Have a history of an allergic reaction to Corlux (C-1073, mifepristone).
Clinical trial NCT01445678 (phase 3, status: completed)
Conditions: complicated intra-abdominal infection
ICD codes: D18.03, C83.73, C84.03, C84.13, C81.73, C81.93, C82.93
Drugs: cxa-201 and metronidazole, meropenem
SMILES: CC1=NC=C(N1CCO)[N+]([O-])=O, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnoses of cIAI.

          -  Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or
             percutaneous draining of an abscess) within 24 hours of (before or after) the first
             dose of study drug.

        Exclusion Criteria:

          -  Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis;
             pancreatic abscess; or pelvic infections.

          -  Complicated intraabdominal infection managed by staged abdominal repair (STAR), open
             abdomen technique including temporary closure of the abdomen, or any situation where
             infection source control is not likely to be achieved.

          -  Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first
             dose of study drug, unless there is a documented treatment failure with such therapy.

          -  Have a concomitant infection at the time of randomization, which requires non-study
             systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only
             gram-positive activity [e.g., daptomycin, vancomycin, linezolid] are allowed).

          -  Severe impairment of renal function (estimated CrCl < 30 mL/min), or requirement for
             peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine
             output over 24 hours).

          -  The presence of hepatic disease at baseline.

          -  Considered unlikely to survive the 4 to 5 week study period.

          -  Any rapidly-progressing disease or immediately life-threatening illness (including
             respiratory failure and septic shock).

          -  Have a documented history of any moderate or severe hypersensitivity or allergic
             reaction to any β-lactam antibacterial (a history of a mild rash followed by
             uneventful re-exposure is not a contraindication to enrollment), including
             cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole,
             or nitroimidazole derivatives.

          -  Women who are pregnant or nursing.
Clinical trial NCT01137812 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin 100 mg, canagliflozin 300 mg, metformin, sulphonylurea
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM and be currently treated with metformin and
             sulphonylurea

          -  Patients in the study must have a HbA1c between >=7 and <=10.5% and a fasting plasma
             glucose (FPG) <300 mg/dL (16.7 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  or a severe hypoglycemic episode within 6 months before screening
Clinical trial NCT00118365 (phase 3, status: completed)
Conditions: precancerous condition
ICD codes: Y95, D69.9, J94.9, L53.9, G47.01, G47.14, P28.9
Drugs: eflornithine, sulindac
SMILES: NCCC[C@@](N)(C(F)F)C(O)=O, CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O
Eligibility criteria:

        Criteria:

          -  History of >= 1 surgically resected adenomatous polyp of the colon measuring >= 3 mm
             within the past 5 years

          -  Screening colonoscopy performed within the past 6 months

          -  All polyps must have been removed during colonoscopy, pathologically examined, and
             archived

          -  No prior surgical resection removing > 40 cm of the colon

          -  No personal or family history of familial polyposis or hereditary non-polyposis colon
             cancer

          -  SWOG 0-1

          -  Bilirubin =< 2.0 mg/dL

          -  AST and ALT =< 2 times normal

          -  Creatinine =< 1.5 mg/dL

          -  Urine protein =<, urine casts 0-3, urine WBC and RBC count 0-5 cells by urinalysis

          -  No history of inflammatory bowel disease

          -  No gastric or duodenal ulcers within the past 12 months

          -  Gastric or duodenal ulcers that were adequately treated > 24 months ago are allowed

          -  No symptomatic gastric or duodenal ulcers

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Must have regional geographic stability over the next 36 months

          -  Pure tone audiometry evaluation normal

          -  Patients with >= 20 dB of uncorrectable hearing loss (for age) of any 2 contiguous
             frequencies are not allowed

          -  No invasive malignancy within the past 5 years except adequately treated nonmelanoma
             skin cancer, level I (or Breslow < 0.76 mm) cutaneous melanoma, Duke's A colon cancer,
             stage I cervical cancer, or stage 0 chronic lymphocytic leukemia

          -  No severe metabolic disorder

          -  No other significant acute or chronic disease that would preclude study participation

          -  No history of abnormal wound healing or repair

          -  No conditions that would confer risk of abnormal wound healing or repair

          -  No history of allergy to NSAIDs or eflornithine

          -  No concurrent chemotherapy

          -  No concurrent corticosteroids on a regular or predictable intermittent basis

          -  No concurrent radiotherapy

          -  Concurrent calcium supplements (=< 1,000 mg/day) allowed

          -  Concurrent lipid-lowering drugs (i.e., high-dose statins) allowed

          -  No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) on a regular or
             predictable intermittent basis

          -  Concurrent aspirin for cardiovascular prophylaxis (i.e., 81 mg/day) allowed

          -  No concurrent anticoagulants on a regular or predictable intermittent basis

          -  No concurrent treatment for gastric or duodenal ulcers
Clinical trial NCT00718224 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: semuloparin sodium, enoxaparin, placebo
SMILES: \N, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        - Knee replacement surgery or revision of at least one component of a knee prosthesis
        implanted ≥ 6 months prior to study entry.

        Exclusion Criteria:

          -  Any major orthopedic surgeries in the 3 months prior to study;

          -  Deep vein thrombosis or pulmonary embolism within the last 12 months, or known
             post-phlebitic syndrome;

          -  Any contraindications to the performance of venography;

          -  High risk of bleeding;

          -  Know allergy to heparin, or enoxaparin, or pork products;

          -  End stage renal disease or patient on dialysis.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00326144 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is able to provide written informed consent before beginning any study related
             procedures

          -  Patient has a documented clinical diagnosis of major depressive disorder

          -  Patient is able to understand and comply with the requirements of the study, as judged
             by a study investigator

        Exclusion Criteria:

          -  Patients with a history of non-compliance as judged by the study investigator

          -  Patients with a known lack of response to previous treatment with quetiapine

          -  Patients who have participated in a clinical trial within 4 weeks of randomization
Clinical trial NCT00446199 (phase 3, status: completed)
Conditions: vasomotor symptoms, hot flashes
ICD codes: J30.0
Drugs: 0.5mg drsp / 0.5mg e2 (bay86-4891), 0.25mg drsp / 0.5mg e2 (bay86-4891), estradiol (e2 0.3mg), placebo
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        - Postmenopausal women >40 years of age experiencing a minimum of 7 to 8 moderate to severe
        hot flushes per day or 50 to 60 moderate to severe hot flushes per week

        Exclusion Criteria:

          -  The usual exclusion criteria for hormone therapy apply

          -  Intake of medications other than hormones affecting hot flushes
Clinical trial NCT00269815 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate hcl
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have successfully completed one of the following earlier ALZA studies:
             CR005992, C-97-033 (and then successfully completed C-98-011), CR005989, or CR005995,
             without significant drug-related adverse events

          -  whose primary care physician agrees that it is appropriate to participate in this
             study

          -  who agree to take only the OROS® (methylphenidate HCl) supplied and no other
             methylphenidate dosage form or other medications for the treatment of ADHD during the
             study

          -  who are able to comply with the study visit schedule and whose parent(s) and teachers
             are willing and able to complete the protocol-specified assessments

          -  who have normal urinalysis, hematological and blood chemistry values or, if values are
             outside the normal range, they are determined not clinically significant by the
             investigator

        Exclusion Criteria:

          -  Patients having clinically significant gastrointestinal problems, including narrowing
             of the gastrointestinal tract

          -  having any coexisting medical condition or are taking any medication that is likely to
             interfere with safe administration of methylphenidate

          -  having a known hypersensitivity to methylphenidate

          -  having a history of high blood pressure or who have a blood pressure (systolic or
             diastolic) equal to or greater than the 95th percentile for age, gender and height

          -  if female, have begun menstruation
Clinical trial NCT00289874 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, comparator: placebo
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients, ages 6 to 14 years, with persistent asthma that is also
             active during allergy season

          -  Patients must demonstrate positive skin prick tests to seasonally relevant geographic
             aeroallergens

        Exclusion Criteria:

          -  Patient cannot have any other acute or chronic pulmonary disorder
Clinical trial NCT00249873 (phase 3, status: completed)
Conditions: atrial fibrillation, vascular risk
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, G21.4, G95.19, I67.3, H34.9, I73.9, Q79.63, Z98.62
Drugs: clopidogrel (sr25990c), placebo
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        To be eligible for ACTIVE A patients must have in same time the three following conditions
        :

          -  Evidence of atrial fibrillation either on one current Electrocardiogram (ECG) or two
             ECGs recorded at two weeks a part during 6 months prior to study enrollment.

          -  Evidence of high risk of vascular events : at least one of the following risk criteria
             must be present :

               -  are 75 years greater;

               -  on treatment for systemic hypertension;

               -  prior stroke, Transient Ischemic Attack (TIA) or non-Central Nervous System
                  (non-CNS) systemic embolus;

               -  left ventricular dysfunction with left ventricular ejection fraction (EF)
                  estimated by echocardiogram or angiogram (radionuclide or contrast) to be < 45%;

               -  peripheral vascular disease (previous peripheral artery revascularization, limb
                  and foot amputation, or the combination of current intermittent claudication and
                  ankle arm systolic blood pressure ratio < 0.9);

               -  age 55 to 74 years and either; f1) diabetes mellitus requiring drug therapy, or
                  f2) documented previous myocardial infarction or documented coronary artery
                  disease.

          -  To have either a contraindication to use an oral anticoagulant treatment or they are
             unwilling to take an oral anticoagulant treatment.

        Exclusion Criteria:

        Patients will be excluded from ACTIVE if any of the following are present :

          -  requirement for clopidogrel (such as recent coronary stent procedure)

          -  requirement for oral anticoagulant (such as prosthetic mechanical heart valve);

          -  prior intolerance to ASA or clopidogrel;

          -  documented peptic ulcer disease within the previous 6 months;

          -  prior intracerebral hemorrhage;

          -  significant thrombocytopenia; (platelet count < 50 x 10(9)/L)

          -  psychosocial reason making study participation impractical;

          -  geographic reason making study participation impractical;

          -  ongoing alcohol abuse;

          -  mitral stenosis,

          -  pregnant or nursing woman or woman of child bearing potential and not on effective
             birth control for at least one month prior to start of study or not willing to
             continue on birth control for duration of study; (severe comorbid condition such that
             the patient is not expected to survive 6 months;

          -  patient currently receiving an investigational pharmacologic agent;
Clinical trial NCT00541450 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, comparator: pioglitazone, matching placebo to pioglitazone, matching placebo to sitagliptin, matching placebo to sita/met fdc
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients between the ages of 18 and 78 with type 2 diabetes mellitus

          -  Patient has not been on any antihyperglycemic agent (Insulin or oral) in the last 3
             months

        Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis

          -  Patient has previously been treated with sitagliptin or has previously been in a study
             using a DPP-4 inhibitor